| Date | Company | Compound | Disease | Type of agreement | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2017-04-26 | Sage Therapeutics (USA - MA) | nomination | CNS diseases | Nomination | ||
| 2017-04-25 | CTI BioPharma - previously known as Cell Therapeutics (USA - WA) - Servier (France) | Pixuvri® (pixantrone) | aggressive B-cell non-Hodgkin lymphoma (NHL) who failed two or three prior lines of therapy | licensing, collaboration | Cancer - Oncology | Licensing agreement |
| 2017-04-25 | BMS (USA - NY) Transgene (France) | TG4010 and Opdivo® | non-small cell lung cancer (NSCLC) | clinical research | Cancer - Oncology | Clinical research agreement |
| 2017-04-25 | European Molecular Biology Laboratory (EMBL) (Germany) Enamine (Ukraine) | library synthesis, medicinal chemistry and biological services | collaboration | Cancer - Oncology | Collaboration agreement | |
| 2017-04-25 | AstraZeneca (UK) | Cambridge Biomedical Campus | opening of new premises | Opening of new premises | ||
| 2017-04-25 | DelMar Pharmaceuticals (USA - CA) Duke University (USA - NC) | VAL-083 (dianhydrogalactitol) | glioblastoma multiforme | collaboration - R&D -research | Cancer - Oncology | Collaboration agreement |
| 2017-04-25 | Amag Pharmaceuticals (USA - MA) | nomination | Nomination | |||
| 2017-04-25 | Quantum Genomics (France) | nomination | Cardiovascular diseases | Nomination | ||
| 2017-04-25 | Sangamo Therapeutics (USA - CA) | member of the board of directors | resignation | Rare diseases - Genetic diseases | Resignation | |
| 2017-04-24 | Amgen (USA - CA) Novartis (Switzerland) | AMG 334 (erenumab), AMG 301, BACE inhibitor program including CNP520 | Alzheimer\'s disease, migraine | development licensing commercialisation | CNS diseases - Neurological diseases - Neurodegenerative diseases | Commercialisation agreement |
| 2017-04-24 | Transgene (France) Sillajen (Republic of Korea) | JX-594/TG6006 (Pexa-Vec -pexastimogene devacirepvec) | hepatocellular carcinoma | development commercialisation | Cancer - Oncology | Milestone |
| 2017-04-24 | OncoMed Pharmaceuticals (USA - CA) | restructuring | Cancer - Oncology | Restructuring | ||
| 2017-04-24 | Paratek Pharmaceuticals (USA - MA) Zai Lab (China) | omadacycline | development - commercialisation | Infectious diseases | Development agreement | |
| 2017-04-21 | Atara Biotherapeutics (USA - CA) Merck&Co (USA - NJ) | ATA129 and Keytruda® (pembrolizumab | platinum resistant or recurrent EBV-associated nasopharyngeal carcinoma | clinical research | Cancer - Oncology | Clinical research agreement |
| 2017-04-20 | Thrombogenics (Belgium) Bicycle Therapeutics (UK) | therapeutics based on Bicycle’s bicyclic peptides | ophtalmological diseases | collaboration - licensing | Ophtalmological diseases | Milestone |
| 2017-04-20 | Allergan (Ireland) TARGET PharmaSolutions | NASH (non-alcoholic steatohepatitis), NAFLD (non-alcoholic fatty liver disease) | clinical research | Hepatic diseases - Liver diseases | Clinical research agreement | |
| 2017-04-19 | Lion Biotechnologies (USA - CA) The University of Texas MD Anderson Cancer Center (USA - TX) | TIL therapy - Tumor infiltrating lymphocytes therapy | ovarian cancer, sarcomas, pancreatic cancer | clinical research | Cancer - Oncology | Clinical research agreement |
| 2017-04-19 | Transgene (France) | members of board of directors | nomination | Cancer - Oncology - Infectious diseases | Nomination | |
| 2017-04-18 | Merck KGaA (Germany) Australian Institute of Tropical Health and Medicine (Australia) Baylor College of Medicine (USA - TX) | schistosomiasis | collaboration | Parasitic diseases | Collaboration agreement | |
| 2017-04-18 | Allergan (Ireland) Novartis (Switzerland) | LJN452 (FXR agonist) and cenicriviroc (CVC) | NASH (non-alcoholic steatohepatitis) | clinical research | Hepatic diseases - Liver diseases | Clinical research agreement |
